Ensuring Research Integrity – Conferences and Workshops Program (CWP)
- Response deadline
- Jul 27, 2026 Closed
- Date posted
- Jun 25, 2026
- Source
- Open notice
Description
This notice solicits applications for projects to plan and implement conferences on research integrity and compliance with 42 C.F.R. part 93. In-person and virtual conferences, or a combination of both, will be considered for funding. This initiative advances Administration priorities to strengthen scientific integrity and research integrity and promote principles of gold standard science – including transparency, reproducibility, and scientific rigor. Conferences must be designed to provide a forum for discussion and produce tangible outcomes related to at least one of the following focus areas: 1) Organization of thematic conference; 2) Skill Building Workshops; and/or 3) Outreach and Education Events. Through these conferences and workshops, the program aims to support the dissemination of evidence-based practices, tools, and approaches that enhance credibility, transparency, and responsible conduct of research and can be applied across institutions and the broader research community.
Classifications
- NAICS93.085
Documents (1)
- DownloadIR-ORI-26-002 Conferences and Workshops Program.pdfapplication/pdf690 KB
Contacts
Similar contracts
- Ensuring Research Integrity – Research on Research Integrity Program (RRI)Due Jul 27, 2026
- Ensuring Research Integrity – Program Development and Evaluation Program (PDE)Due Jul 27, 2026
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food SpecimensDue Apr 1, 2027
- Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not AllowedDue Apr 1, 2027
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)Due Jul 14, 2026